BE897003A - Preparations pharmaceutiques topiques presentant une activite antiseptique et une activite anti-inflammatoire amelioree et procede pour les preparer - Google Patents
Preparations pharmaceutiques topiques presentant une activite antiseptique et une activite anti-inflammatoire amelioree et procede pour les preparer Download PDFInfo
- Publication number
- BE897003A BE897003A BE1/10809A BE1010809A BE897003A BE 897003 A BE897003 A BE 897003A BE 1/10809 A BE1/10809 A BE 1/10809A BE 1010809 A BE1010809 A BE 1010809A BE 897003 A BE897003 A BE 897003A
- Authority
- BE
- Belgium
- Prior art keywords
- sep
- ointment
- dihydroxy
- diene
- bis
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 20
- 230000003110 anti-inflammatory effect Effects 0.000 title claims description 12
- 239000000825 pharmaceutical preparation Substances 0.000 title claims description 10
- 230000000699 topical effect Effects 0.000 title claims description 10
- 230000002421 anti-septic effect Effects 0.000 title claims description 8
- 239000002674 ointment Substances 0.000 claims description 47
- 238000002360 preparation method Methods 0.000 claims description 28
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Substances CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 18
- 239000000203 mixture Substances 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000003883 ointment base Substances 0.000 claims description 11
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 11
- -1 5-chlorophenyl Chemical group 0.000 claims description 7
- 239000000470 constituent Substances 0.000 claims description 5
- 239000000839 emulsion Substances 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 239000000969 carrier Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- 238000009472 formulation Methods 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 239000003981 vehicle Substances 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 3
- SNKKBYWIYDOXGC-IYEMJOQQSA-N hexane;(2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanoic acid Chemical compound CCCCCC.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O SNKKBYWIYDOXGC-IYEMJOQQSA-N 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 238000011282 treatment Methods 0.000 description 30
- 201000004624 Dermatitis Diseases 0.000 description 16
- 239000000243 solution Substances 0.000 description 14
- 208000010668 atopic eczema Diseases 0.000 description 10
- 208000024891 symptom Diseases 0.000 description 10
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 9
- 239000003242 anti bacterial agent Substances 0.000 description 9
- 230000000844 anti-bacterial effect Effects 0.000 description 8
- 239000003246 corticosteroid Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 229960003260 chlorhexidine Drugs 0.000 description 7
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 6
- 238000003756 stirring Methods 0.000 description 6
- 229940088710 antibiotic agent Drugs 0.000 description 5
- 239000003995 emulsifying agent Substances 0.000 description 5
- 239000012188 paraffin wax Substances 0.000 description 5
- 208000017520 skin disease Diseases 0.000 description 5
- 239000001993 wax Substances 0.000 description 5
- QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 230000001857 anti-mycotic effect Effects 0.000 description 4
- 239000008387 emulsifying waxe Substances 0.000 description 4
- JWRMHDSINXPDHB-OJAGFMMFSA-N flumethasone pivalate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)COC(=O)C(C)(C)C)(O)[C@@]2(C)C[C@@H]1O JWRMHDSINXPDHB-OJAGFMMFSA-N 0.000 description 4
- 229960000890 hydrocortisone Drugs 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 229960005205 prednisolone Drugs 0.000 description 4
- 239000003755 preservative agent Substances 0.000 description 4
- 239000002689 soil Substances 0.000 description 4
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 4
- OWFJMIVZYSDULZ-PXOLEDIWSA-N (4s,4ar,5s,5ar,6s,12ar)-4-(dimethylamino)-1,5,6,10,11,12a-hexahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O OWFJMIVZYSDULZ-PXOLEDIWSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- 208000003322 Coinfection Diseases 0.000 description 3
- 208000005373 Dyshidrotic Eczema Diseases 0.000 description 3
- 206010020565 Hyperaemia Diseases 0.000 description 3
- 208000002193 Pain Diseases 0.000 description 3
- 201000011152 Pemphigus Diseases 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 239000002543 antimycotic Substances 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 208000013046 dyshidrosis Diseases 0.000 description 3
- ACGUYXCXAPNIKK-UHFFFAOYSA-N hexachlorophene Chemical compound OC1=C(Cl)C=C(Cl)C(Cl)=C1CC1=C(O)C(Cl)=CC(Cl)=C1Cl ACGUYXCXAPNIKK-UHFFFAOYSA-N 0.000 description 3
- 229960004068 hexachlorophene Drugs 0.000 description 3
- 230000007803 itching Effects 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 201000001976 pemphigus vulgaris Diseases 0.000 description 3
- 201000011414 pompholyx Diseases 0.000 description 3
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
- SWECWXGUJQLXJF-BTJKTKAUSA-N Dimetindene maleate Chemical compound OC(=O)\C=C/C(O)=O.CN(C)CCC=1CC2=CC=CC=C2C=1C(C)C1=CC=CC=N1 SWECWXGUJQLXJF-BTJKTKAUSA-N 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 241000588748 Klebsiella Species 0.000 description 2
- 229930193140 Neomycin Natural products 0.000 description 2
- 239000004100 Oxytetracycline Substances 0.000 description 2
- 239000005662 Paraffin oil Substances 0.000 description 2
- NCXMLFZGDNKEPB-UHFFFAOYSA-N Pimaricin Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCC(C)OC(=O)C=CC2OC2CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 NCXMLFZGDNKEPB-UHFFFAOYSA-N 0.000 description 2
- 241000588769 Proteus <enterobacteria> Species 0.000 description 2
- 241000589516 Pseudomonas Species 0.000 description 2
- 206010037888 Rash pustular Diseases 0.000 description 2
- 206010040880 Skin irritation Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- 239000003429 antifungal agent Substances 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000000265 homogenisation Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000005005 intertrigo Diseases 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 229960003255 natamycin Drugs 0.000 description 2
- NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 description 2
- 229960004927 neomycin Drugs 0.000 description 2
- 229960000625 oxytetracycline Drugs 0.000 description 2
- 235000019366 oxytetracycline Nutrition 0.000 description 2
- IZUPBVBPLAPZRR-UHFFFAOYSA-N pentachlorophenol Chemical compound OC1=C(Cl)C(Cl)=C(Cl)C(Cl)=C1Cl IZUPBVBPLAPZRR-UHFFFAOYSA-N 0.000 description 2
- 239000003761 preservation solution Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 208000029561 pustule Diseases 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- 230000036556 skin irritation Effects 0.000 description 2
- 231100000475 skin irritation Toxicity 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000012976 tarts Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 229960005294 triamcinolone Drugs 0.000 description 2
- GFNANZIMVAIWHM-OBYCQNJPSA-N triamcinolone Chemical compound O=C1C=C[C@]2(C)[C@@]3(F)[C@@H](O)C[C@](C)([C@@]([C@H](O)C4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 GFNANZIMVAIWHM-OBYCQNJPSA-N 0.000 description 2
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 2
- GUONGCJWVVTENV-DZVXQVNQSA-N (4s,4ar,5s,5ar,6s,12ar)-4-(dimethylamino)-1,5,6,10,11,12a-hexahydroxy-6-methyl-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;(8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1h-cyc Chemical compound Cl.O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1.C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]4(O)C(=O)C3=C(O)C2=C1O GUONGCJWVVTENV-DZVXQVNQSA-N 0.000 description 1
- YSGQGNQWBLYHPE-CFUSNLFHSA-N (7r,8r,9s,10r,13s,14s,17s)-17-hydroxy-7,13-dimethyl-2,6,7,8,9,10,11,12,14,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-3-one Chemical compound C1C[C@]2(C)[C@@H](O)CC[C@H]2[C@@H]2[C@H](C)CC3=CC(=O)CC[C@@H]3[C@H]21 YSGQGNQWBLYHPE-CFUSNLFHSA-N 0.000 description 1
- IHZIQQBUAKZVCI-XTANLHRZSA-N 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole;(8s,9s,10r,11s,13s,14s,17r)-11,17-dihydroxy-10,13-dimethyl-17-[2-(4-methylpiperazin-1-yl)acetyl]-7,8,9,11,12,14,15,16-octahydro-6h-cyclopenta[a]phenanthren-3-one;nitric acid;hydrochl Chemical compound Cl.O[N+]([O-])=O.ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1.C1CN(C)CCN1CC(=O)[C@]1(O)[C@@]2(C)C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2CC1 IHZIQQBUAKZVCI-XTANLHRZSA-N 0.000 description 1
- FDCJDKXCCYFOCV-UHFFFAOYSA-N 1-hexadecoxyhexadecane Chemical compound CCCCCCCCCCCCCCCCOCCCCCCCCCCCCCCCC FDCJDKXCCYFOCV-UHFFFAOYSA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010004078 Balanoposthitis Diseases 0.000 description 1
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 description 1
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 102100026933 Myelin-associated neurite-outgrowth inhibitor Human genes 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010061926 Purulence Diseases 0.000 description 1
- 206010037868 Rash maculo-papular Diseases 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000037374 absorbed through the skin Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003470 adrenal cortex hormone Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000009285 allergic inflammation Effects 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 description 1
- 229940064004 antiseptic throat preparations Drugs 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 208000010247 contact dermatitis Diseases 0.000 description 1
- 238000011443 conventional therapy Methods 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000002683 foot Anatomy 0.000 description 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 208000012965 maculopapular rash Diseases 0.000 description 1
- CZBOZZDZNVIXFC-VRRJBYJJSA-N mazipredone Chemical compound C1CN(C)CCN1CC(=O)[C@]1(O)[C@@]2(C)C[C@H](O)[C@@H]3[C@@]4(C)C=CC(=O)C=C4CC[C@H]3[C@@H]2CC1 CZBOZZDZNVIXFC-VRRJBYJJSA-N 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 239000013643 reference control Substances 0.000 description 1
- 231100000075 skin burn Toxicity 0.000 description 1
- 101150008563 spir gene Proteins 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000012049 topical pharmaceutical composition Substances 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 239000000003 vaginal tablet Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU821911A HU187724B (en) | 1982-06-14 | 1982-06-14 | Process for producing antiseptic pharmaceutical compositions of improved antiflammatoric activity for topical application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BE897003A true BE897003A (fr) | 1983-12-09 |
Family
ID=10956814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BE1/10809A BE897003A (fr) | 1982-06-14 | 1983-06-09 | Preparations pharmaceutiques topiques presentant une activite antiseptique et une activite anti-inflammatoire amelioree et procede pour les preparer |
Country Status (9)
| Country | Link |
|---|---|
| JP (1) | JPS5962525A (de) |
| AT (1) | AT382312B (de) |
| BE (1) | BE897003A (de) |
| CH (1) | CH656799A5 (de) |
| DE (1) | DE3321487A1 (de) |
| FR (1) | FR2528310B1 (de) |
| GB (1) | GB2125290B (de) |
| HU (1) | HU187724B (de) |
| IT (1) | IT1194572B (de) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EA014292B1 (ru) * | 2008-02-18 | 2010-10-29 | Открытое Акционерное Общество "Нижегородский Химико-Фармацевтический Завод" (Оао "Нижфарм") | Лечебно-профилактическое средство, обладающее антибактериальным и спермицидным действием |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2539M (fr) * | 1963-03-15 | 1964-05-19 | Charles Sidi | Pellicule plastique a propriétés thérapeutiques. |
-
1982
- 1982-06-14 HU HU821911A patent/HU187724B/hu not_active IP Right Cessation
-
1983
- 1983-06-09 BE BE1/10809A patent/BE897003A/fr not_active IP Right Cessation
- 1983-06-13 AT AT0216783A patent/AT382312B/de not_active IP Right Cessation
- 1983-06-13 FR FR8309736A patent/FR2528310B1/fr not_active Expired
- 1983-06-13 CH CH3233/83A patent/CH656799A5/de not_active IP Right Cessation
- 1983-06-13 GB GB08316087A patent/GB2125290B/en not_active Expired
- 1983-06-14 IT IT21607/83A patent/IT1194572B/it active
- 1983-06-14 JP JP58105063A patent/JPS5962525A/ja active Pending
- 1983-06-14 DE DE3321487A patent/DE3321487A1/de not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| IT1194572B (it) | 1988-09-22 |
| GB2125290A (en) | 1984-03-07 |
| ATA216783A (de) | 1986-07-15 |
| GB2125290B (en) | 1985-10-02 |
| FR2528310B1 (fr) | 1987-04-24 |
| IT8321607A1 (it) | 1984-12-14 |
| HU187724B (en) | 1986-02-28 |
| DE3321487A1 (de) | 1983-12-15 |
| CH656799A5 (de) | 1986-07-31 |
| AT382312B (de) | 1987-02-10 |
| JPS5962525A (ja) | 1984-04-10 |
| FR2528310A1 (fr) | 1983-12-16 |
| GB8316087D0 (en) | 1983-07-20 |
| IT8321607A0 (it) | 1983-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP4014114B2 (ja) | 抗菌作用の増強剤 | |
| JP2010509374A (ja) | 局所製剤とその用法 | |
| CZ390099A3 (cs) | Lotion na bázi emulzí aktivního vitamínu D3 | |
| EP3409267A1 (de) | Verwendung von octenidindihydrochlorid für halbfeste zubereitungen | |
| JPH01503061A (ja) | 局所的メトロニダゾール製剤 | |
| WO2024175915A1 (en) | Compositions for topical administration | |
| JPH05502440A (ja) | イブプロフェン摩砕物及びこれを含有する局所用組成物 | |
| FR2977493A1 (fr) | Nouvelle composition anesthesique stable pour la reduction des reactions cutanees | |
| EP1885374A2 (de) | Pharmazeutische zusammensetzung mit einer fettsalbe und vitamin d oder derivaten in löslicher form | |
| AU674411B2 (en) | Compositions for the treatment of inflammatory proliferative skin disease and their use | |
| FR2612397A1 (fr) | Compositions pharmaceutiques contenant du nedocromil ou l'un de ses derives | |
| CZ868686A3 (en) | Primicin-containing colloidal elementary gel, and process for preparing thereof | |
| FR2528310A1 (fr) | Preparations pharmaceutiques topiques presentant une activite antiseptique et une activite antiinflammatoire amelioree et procede pour les preparer | |
| WO2008067774A1 (fr) | Composition pharmaceutique antifongique | |
| AU2003227095B2 (en) | Use of topical compositions for the control of microbial diseases of the nail | |
| EP0851755A1 (de) | Antiseptische dermatologische zusammensetzung und ein verfahren zu seiner herstellung | |
| DE3904674A1 (de) | Verwendung einer wirkstoffkombination zur behandlung rheumatischer erkrankungen | |
| CN117243990B (zh) | 一种用于治疗头皮脂溢性皮炎的喷雾杀菌剂及制备方法 | |
| WO2006122472A1 (fr) | Onguent antithyroïdien à usage externe et préparation de celui-ci | |
| JPH03181417A (ja) | 局所用抗菌剤 | |
| JPS585885B2 (ja) | 新規薬用軟膏 | |
| UA128615C2 (uk) | Мазь емульсійна на остові фітокомплексу для терапії хейлітів різної етіології | |
| EP1628672A2 (de) | Zusammensetzung und verwendung von in ätherischen ölen von melaleuca alternifolia oder melaleuca quinquenervia gelöstem reinem jod | |
| GB2279567A (en) | Topical 8-hydroxyquinoline compositions | |
| CH709877A2 (fr) | Préparations antifongiques destinées au traitement local des onychomycoses. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RE | Patent lapsed |
Owner name: ALKALOIDA VEGYESZETI GYAR Effective date: 19910630 |